Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 2/20 | 0.40 |
| ▸ | TRPC6 | Q9Y210 | 3/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.38 |
| ▸ | CTSB | P07858 | 2/20 | 0.37 |
| ▸ | CTSS | P25774 | 2/20 | 0.37 |
| ▸ | CTSK | P43235 | 2/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | CCR1 | P32246 | 3/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16752883 | 0.87 | NR1H2 (0.36) | SLC6A9NR1H2CHRM4NR1H3 | |
| SCHEMBL15970130 | 0.87 | IP6K1 (0.39) | SLC6A9NR1H2NR1H3 | |
| SCHEMBL28036149 | 0.86 | SLC6A9 (0.40) | SLC6A9TRPC6NR1H2CHRM4NR1H3 | |
| SCHEMBL16752888 | 0.84 | NR1H2 (0.39) | NR1H2CHRM4NR1H3 | |
| SCHEMBL3503419 | 0.83 | SIRT6 (0.57) | — | |
| SCHEMBL2442056 | 0.81 | SLC6A9 (0.36) | SLC6A9TRPC6NR1H2CHRM4NR1H3 | |
| SCHEMBL28036150 | 0.81 | HTR1A (0.48) | — | |
| SCHEMBL16371697 | 0.80 | GFER (0.47) | SLC6A9NR1H2CTSBCTSSCTSK | |
| SCHEMBL11294977 | 0.79 | CCR1 (0.46) | TRPC6CCR1 | |
| SCHEMBL15924272 | 0.78 | MAPT (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136614-A1 | 2,7-SUBSTITUTED PYRROLO[2,1-F][1,2,4]TRIAZINE COMPOUND HAVING PROTEIN KINASE INHIBITORY ACTIVITY | MAGICBULLETTHERAPEUTICS CO., LTD. (KR) | 2025-05-01 | — | — | US | disclosed |
| EP-4442691-A1 | 2,7-SUBSTITUTED PYRROLO[2,1-F][1,2,4]TRIAZINE COMPOUND HAVING PROTEIN KINASE INHIBITORY ACTIVITY | Magicbullettherapeutics Co., Ltd. (KR) | 2024-10-09 | — | — | EP | disclosed |
| WO-2023140629-A1 | 2,7-SUBSTITUTED PYRROLO[2,1-F][1,2,4]TRIAZINE COMPOUND HAVING PROTEIN KINASE INHIBITORY ACTIVITY | 닥터아이앤비(주) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023101387-A1 | 2,7-SUBSTITUTED PYRROLO[2,1-F][1,2,4]TRIAZINE COMPOUND HAVING PROTEIN KINASE INHIBITORY ACTIVITY | 연세대학교 산학협력단 | 2023-06-08 | — | — | WO | disclosed |
| EP-2883875-B1 | N2,N4-BIS(4-(PIPERAZINE-1-YL)PHENYL)PIRIMIDINE-2,4-DIAMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER | KOREA RES INST CHEMICAL TECH (KR) | 2016-12-28 | — | — | EP | disclosed |
| CN-105384694-A | Substituted aminopyrimidine derivative, preparation method therefor and pharmaceutical application thereof | SICHUAN HAISCO PHARMACEUTICAL CO LTD | 2016-03-09 | — | — | CN | disclosed |
| US-9199944-B2 | N2,N4-bis(4-(piperazine-1-yl)phenyl)pirimidine-2,4-diamine derivative or pharmaceutically acceptable salt thereof, and composition containing same as active ingredient for preventing or treating cancer | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2015-12-01 | — | — | US | disclosed |
| EP-2883875-A1 | N2,N4-BIS(4-(PIPERAZINE-1-YL)PHENYL)PIRIMIDINE-2,4-DIAMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER | Korea Reserach Institute Of Chemical Technology (KR) | 2015-06-17 | — | — | EP | disclosed |
| US-20150152069-A1 | N2,N4-BIS(4-(PIPERAZINE-1-YL)PHENYL)PIRIMIDINE-2,4-DIAMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER | PINOTBIO, INC. (KR) | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136614-A1 | 2,7-SUBSTITUTED PYRROLO[2,1-F][1,2,4]TRIAZINE COMPOUND HAVING PROTEIN KINASE INHIBITORY ACTIVITY | STK25, MAP3K15, MAP3K5 | SLC6A9 4358/4885TRPC6 1326/4885NR1H2 4271/4885 |
| US-20150152069-A1 | N2,N4-BIS(4-(PIPERAZINE-1-YL)PHENYL)PIRIMIDINE-2,4-DIAMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER | TNK2, NPM1, NEK4 | SLC6A9 3818/4885TRPC6 1776/4885NR1H2 3706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.